Moderna is in a powerful uptrend, with the stock up 163.4% over the past year and currently trading at 98.0% of its 52-week range (52-week low: $22.28, high: $81.40). The price closed at $79.76 on July 2, 2026, near the top of the range, indicating strong momentum and bullish sentiment. This positioning near highs suggests the market is pricing in positive catalysts, but also raises the risk of overextension. Short-term momentum is exceptionally strong: the 1-month price change is +74.8% and the 3-month change is +62.1%, significantly outpacing the S&P 500's 1-month decline of -1.25% and 3-month gain of +13.56%. The 1-month relative strength of 76.0% versus the S&P 500 confirms the stock's recent outperformance. This acceleration from the longer-term trend (1-year +163.4%) suggests a breakout move, likely fueled by the FDA flu vaccine news in late June. Key support lies at the 52-week low of $22.28, while resistance is at the 52-week high of $81.40. A breakout above $81.40 would signal a continuation of the uptrend, potentially targeting new highs. The stock's beta of 0.94 indicates volatility roughly in line with the market, meaning the recent sharp moves are driven by company-specific catalysts rather than broad market swings. The short ratio of 10.94 days suggests elevated short interest, which could fuel a short squeeze if positive news continues.

Moderna's revenue trajectory has been volatile, heavily dependent on COVID-19 vaccine sales. In Q4 2025, revenue was $678 million, down 29.1% year-over-year from $956 million in Q4 2024, reflecting declining pandemic demand. However, the company is diversifying: product sales for the latest quarter were $1.052 billion, and the pipeline includes a flu vaccine with FDA panel support. The multi-quarter trend shows revenue declining from $1.016 billion in Q3 2025 to $678 million in Q4 2025, indicating a deceleration in the core COVID franchise. The company remains unprofitable, with a net loss of $826 million in Q4 2025 and a trailing twelve-month net income of -$2.054 billion. Gross margin was 33.3% in Q4 2025, down from 72.3% in Q3 2024, reflecting a shift in product mix and lower-margin sales. Operating margin was -126.4% in Q4 2025, indicating that operating expenses (especially R&D of $775 million) far exceed gross profit. The net margin of -121.8% shows deep losses, though this is typical for a biotech investing heavily in R&D. Moderna's balance sheet is relatively strong: it has $2.595 billion in cash at the end of Q4 2025, with a current ratio of 3.29 and a debt-to-equity ratio of 0.22, indicating low leverage. Free cash flow was positive $912 million in Q4 2025, but the trailing twelve-month free cash flow is -$2.054 billion, reflecting heavy investment. ROE is -32.6%, and ROA is -13.1%, both negative due to losses. The company generates enough cash from operations ($951 million in Q4 2025) to fund capex ($39 million), but overall cash burn remains high.